Table 3.
Associated factors of the total hospitalization costs in COVID-19 cases.
| Characteristics | Median (IQR) (× $1,000) | % Differencea,d (95%CI) |
|---|---|---|
| ICU therapyb | ||
| No | 2.7 (3.3) | Reference |
| Yes | 19.0 (53.1) | 353.0 (253.8, 479.9) |
| Anti-infective drug usage | ||
| No | 2.4 (2.2) | Reference |
| Yes | 4.1 (6.4) | 58.4 (40.8, 78.1) |
| Antiviral drug usage | ||
| No | 2.9 (4.2) | Reference |
| Yes | 2.6 (1.4) | 16.0 (−7.9, 46.0) |
| ECMO therapyc | ||
| No | 2.8 (3.7) | Reference |
| Yes | 154.5 (88.3) | 1524.8 (887.3, 2574.0) |
| Angiotensin drugs usage | ||
| No | 2.8 (3.7) | Reference |
| Yes | 92.5 (137.6) | 898.9 (562.8, 1405.5) |
| Chloroquine phosphate usage | ||
| No | 2.9 (4.0) | Reference |
| Yes | 2.7 (0.6) | 13.4 (−36.3, 102.1) |
a
Adjusted for sex, age, and hospital level of admission.
b
ICU, Intensive care unit.
c
ECMO, Extracorporeal membrane oxygenation.
d
The costs were calculated at the exchange rate between RMB and U.S dollars on August 1, 2020.